Sceletium Tortuosum and Mesembrine: a Potential Alternative Treatment for Depression Rebecca Schell Scripps College
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) Patent Application Publication (10) Pub. No.: US 2016/017.4603 A1 Abayarathna Et Al
US 2016O174603A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/017.4603 A1 Abayarathna et al. (43) Pub. Date: Jun. 23, 2016 (54) ELECTRONIC VAPORLIQUID (52) U.S. Cl. COMPOSITION AND METHOD OF USE CPC ................. A24B 15/16 (2013.01); A24B 15/18 (2013.01); A24F 47/002 (2013.01) (71) Applicants: Sahan Abayarathna, Missouri City, TX 57 ABSTRACT (US); Michael Jaehne, Missouri CIty, An(57) e-liquid for use in electronic cigarettes which utilizes- a TX (US) vaporizing base (either propylene glycol, vegetable glycerin, (72) Inventors: Sahan Abayarathna, MissOU1 City,- 0 TX generallyor mixture at of a 0.001 the two) g-2.0 mixed g per with 1 mL an ratio. herbal The powder herbal extract TX(US); (US) Michael Jaehne, Missouri CIty, can be any of the following:- - - Kanna (Sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Salvia eivinorm, Kratom (Mitragyna speciosa), Celandine (21) Appl. No.: 14/581,179 poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia Californica), Sinicuichi (Heimia Salicifolia), (22) Filed: Dec. 23, 2014 St. John's Wort (Hypericum perforatum), Yerba lenna yesca A rtemisia scoparia), CaleaCal Zacatechichihichi (Calea(Cal termifolia), Leonurus Sibericus (Leonurus Sibiricus), Wild dagga (Leono Publication Classification tis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffiisa), Kava (Piper methysticum), Scotch broom (51) Int. Cl. tops (Cytisus scoparius), Valarien (Valeriana officinalis), A24B 15/16 (2006.01) Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca A24F 47/00 (2006.01) virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifo A24B I5/8 (2006.01) lium pretense), and/or combinations therein. -
WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 33/16 (2006.01) A61K 31/7048 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 33/14 (2006.01) A61K 31/70 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, A61K 33/18 (2006.01) A61K 31/4196 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (21) International Application Number: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, PCT/US20 13/030788 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (22) International Filing Date: ZM, ZW. 13 March 2013 (13.03.2013) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/612,689 19 March 2012 (19.03.2012) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Avenue, New Haven, CT 065 10 (US). -
Investigation Into Potential Endocrine Disruptive Effects of Sceletium Tortuosum
Investigation into potential endocrine disruptive effects of Sceletium tortuosum by Letitia Louw Dissertation presented for the degree of Master of Science in the Faculty of Science at Stellenbosch University Supervisor: Prof C. Smith Co-supervisor: Prof AC. Swart March 2018 Stellenbosch University https://scholar.sun.ac.za Declaration By submitting this dissertation electronically, I declare that the entirety of the work contained therein is my own, original work, that I am the sole author thereof (save to the extent explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch University will not infringe any third party rights and that I have not previously in its entirety or in part submitted it for obtaining any qualification. March 2018 Copyright © 2018 Stellenbosch University All rights reserved i Stellenbosch University https://scholar.sun.ac.za What if I fall? Oh, but darling what if you fly? ii Stellenbosch University https://scholar.sun.ac.za ABSTRACT Depression has been recognised by the World Health Organisation (WHO) as the leading cause of disability, affecting an estimated 300 million people globally. To date antidepressants are prescribed as the first step in the treatment strategy. However, finding the appropriate antidepressant is often a lengthy process and is usually accompanied by side effects. A major and often unexpected side effect is reduced sexual function, which has been reported to aggravate depression and could possibly lead to poor compliance to medication. Sceletium tortuosum is a native South African plant, which has exhibited both antidepressant and anxiolytic properties. Although the exact mechanism of action remains to be elucidated, there are currently two hypotheses which attempt to explain it’s mechanism of action. -
Study Protocol 64565111EDI1002
NCT03586830 Janssen Research & Development * Clinical Protocol Protocol Title A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose- ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus Short Title Evaluation of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus Protocol 64565111OBE2002; Phase 2b AMENDMENT 1 JNJ-64565111 *Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol. US sites of this study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312).] Status: Approved Date: 23 August 2018 Prepared by: Janssen Research & Development, LLC EDMS number: EDMS-ERI-156156741, 2.0 GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements. Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. -
(12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S. -
General Pharmacology
GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple -
Potential Natural Product Phosphodiesterase Inhibitors
University of Mississippi eGrove Electronic Theses and Dissertations Graduate School 1-1-2013 Potential Natural Product Phosphodiesterase Inhibitors Michael John Cunningham University of Mississippi Follow this and additional works at: https://egrove.olemiss.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Cunningham, Michael John, "Potential Natural Product Phosphodiesterase Inhibitors" (2013). Electronic Theses and Dissertations. 1343. https://egrove.olemiss.edu/etd/1343 This Thesis is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information, please contact [email protected]. POTENTIAL NATURAL PRODUCT PHOSPHODIESTERASE INHIBITORS A Thesis presented in partial fulfillment of requirements for the degree of Master of Science in the Department of Pharmacognosy, School of Pharmacy The University of Mississippi by Michael J. Cunningham August 2013 Copyright Michael Cunningham 2013 ALL RIGHTS RESERVED ABSTRACT Three different studies set forth to investigate the role of phosphodiesterase (PDE) enzyme inhibitors in sexual dysfunction and mood regulation. First, natural products were screened by computer modeling of PDE5A1. Second, compounds were isolated from a plant traditionally used as an aphrodisiac. Third, a new synthesis of psychoactive PDE4 inhibitor was attempted. An in silico screen was performed using chemical structures of isolated compounds thought to have some PDE inhibitory activity based on traditional use of the plants. A collection of compounds with structures similar to known natural product inhibitors was also included in the docking library. Glide docking software (Schrödinger) was used to score compounds based on their modeled interactions with the PDE5A1 enzyme. -
Regulation of Alkaloid Biosynthesis in Plants
CONTRIBUTORS Numbers in parentheses indicate the pages on which the authors’ contributions begin. JAUME BASTIDA (87), Departament de Productes Naturals, Facultat de Farma` cia, Universitat de Barcelona, 08028 Barcelona, Spain YEUN-MUN CHOO (181), Department of Chemistry, University of Malaya, 50603 Kuala Lumpur, Malaysia PETER J. FACCHINI (1), Department of Biological Sciences, University of Calgary, Calgary, AB, Canada TOH-SEOK KAM (181), Department of Chemistry, University of Malaya, 50603 Kuala Lumpur, Malaysia RODOLFO LAVILLA (87), Parc Cientı´fic de Barcelona, Universitat de Barcelona, 08028 Barcelona, Spain DANIEL G. PANACCIONE (45), Division of Plant and Soil Sciences, West Virginia University, Morgantown, WV 26506-6108, USA CHRISTOPHER L. SCHARDL (45), Department of Plant Pathology, University of Kentucky, Lexington, KY 40546-0312, USA PAUL TUDZYNSKI (45), Institut fu¨r Botanik, Westfa¨lische Wilhelms Universita¨tMu¨nster, Mu¨nster D-48149, Germany FRANCESC VILADOMAT (87), Departament de Productes Naturals, Facultat de Farma` cia, Universitat de Barcelona, 08028 Barcelona, Spain vii PREFACE This volume of The Alkaloids: Chemistry and Biology is comprised of four very different chapters; a reflection of the diverse facets that comprise the study of alkaloids today. As awareness of the global need for natural products which can be made available as drugs on a sustainable basis increases, so it has become increas- ingly important that there is a full understanding of how key metabolic pathways can be optimized. At the same time, it remains important to find new biologically active alkaloids and to elucidate the mechanisms of action of those that do show potentially useful or novel biological effects. Facchini, in Chapter 1, reviews the significant studies that have been conducted with respect to how the formation of alkaloids in their various diverse sources are regulated at the molecular level. -
Natural Products of Relevance in the Prevention and Supportive Treatment of Depression
Psychiatr. Pol. 2015; 49(3): 435–453 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/PP/29367 Natural products of relevance in the prevention and supportive treatment of depression Bożena Muszyńska1, Maciej Łojewski 1,Jacek Rojowski 2, Włodzimierz Opoka 2, Katarzyna Sułkowska-Ziaja1 1Chair and Department of Pharmaceutical Botany, Jagiellonian University Medical College Head: prof. dr hab. H. Ekiert 2Chair of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College Head: dr hab. W. Opoka, prof. of Jagiellonian University Summary The use of herbs or their parts: leaves, roots, rhizomes, flowers, seeds, natural strains, as well as extracts or isolated metabolites is becoming more and more popular. Natural remedies not only act prophylactically, but also help to alleviate symptoms of many diseases and enhance the overall functioning of the internal organs. Many raw materials of natural origin plays a role in treatment of health problems, and also in case of serious diseases such as depression. Depres- sion (affective disorder) now affects about 10% of the population, but in next few years due to the development of civilization and increasing pace of life, the probable number of people suffering from this disease can grow rapidly. Natural raw materials such as Bacopa monnieri, Crocus sativus, Eleutherococcus senticosus, Griffonia simplicifolia, Hypericum perforatum, Sceletium tortuosum, Piper methysticum, Rhodiola rosea, Aspalathus linearis, Camellia sinensis, Ficus carica, Lycium chinense, Cuminum cyminum, Panax Ginseng can effectively assist the prevention and treatment of depression. Daily diet may also have positive effect in prevention of this disease. -
Plant List 2021-06-24
Plant List 2021-10-02 (08:28) Plant Plant Name Botanical Name in Price Stock Per Unit AFRICAN DREAM ROOT - 1 Silene capensis Yes R92 AFRICAN DREAM ROOT - 2 Silene undulata Yes R92 AFRICAN POTATO Hypoxis hemerocallidea Yes R89 AFRICAN POTATO - SILVER-LEAFED STAR FLOWER Hypoxis rigidula Yes R89 AGASTACHE - GOLDEN JUBILEE Agastache foeniculum No R52 AGASTACHE - HYSSOP, WRINKLED GIANT HYSSOP Agastache rugosa Yes R59 AGASTACHE - LICORICE MINT HYSSOP Agastache rupestris No R59 AGASTACHE - PINK POP Agastache astromontana No R54 AGRIMONY Agrimonia eupatoria No R54 AJWAIN Trachyspermum ammi No R49 ALFALFA Medicago sativa Yes R59 ALOE VERA - ORANGE FLOWER A. barbadensis Yes R59 ALOE VERA - YELLOW FLOWER syn A. barbadensis 'Miller' No R59 AMARANTH - ‘LOVE-LIES-BLEEDING’ Amaranthus caudatus No R49 AMARANTH - CHINESE SPINACH Amaranthus species No R49 AMARANTH - GOLDEN GIANT Amaranthus cruentas No R49 AMARANTH - RED LEAF Amaranthus cruentas No R49 ARTICHOKE - GREEN GLOBE Cynara scolymus Yes R54 ARTICHOKE - JERUSALEM Helianthus tuberosus Yes R64 ARTICHOKE - PURPLE GLOBE Cynara scolymus No R54 ASHWAGANDA, INDIAN GINSENG Withania somniferia Yes R59 ASPARAGUS - GARDEN Asparagus officinalis Yes R54 BALLOON FLOWER - PURPLE Platycodon grandiflorus 'Apoyama' Yes R59 BALLOON FLOWER - WHITE Platycodon grandiflorus var. Albus No R59 BASIL - CAMPHOR Ocimum kilimandscharicum Yes R59 BASIL HOLY - GREEN TULSI, RAM TULSI Ocimum Sanctum Yes R54 BASIL HOLY - TULSI KAPOOR Ocimum sanctum Linn. No R54 BASIL HOLY - TULSI TEMPERATE Ocimum africanum No R54 BASIL HOLY - TULSI -
Medicinal Plants Used in the Treatment of Human Immunodeficiency Virus
International Journal of Molecular Sciences Review Medicinal Plants Used in the Treatment of Human Immunodeficiency Virus Bahare Salehi 1,2 ID , Nanjangud V. Anil Kumar 3 ID , Bilge ¸Sener 4, Mehdi Sharifi-Rad 5,*, Mehtap Kılıç 4, Gail B. Mahady 6, Sanja Vlaisavljevic 7, Marcello Iriti 8,* ID , Farzad Kobarfard 9,10, William N. Setzer 11,*, Seyed Abdulmajid Ayatollahi 9,12,13, Athar Ata 13 and Javad Sharifi-Rad 9,13,* ID 1 Medical Ethics and Law Research Center, Shahid Beheshti University of Medical Sciences, 88777539 Tehran, Iran; [email protected] 2 Student Research Committee, Shahid Beheshti University of Medical Sciences, 22439789 Tehran, Iran 3 Department of Chemistry, Manipal Institute of Technology, Manipal University, Manipal 576104, India; [email protected] 4 Department of Pharmacognosy, Gazi University, Faculty of Pharmacy, 06330 Ankara, Turkey; [email protected] (B.¸S.);[email protected] (M.K.) 5 Department of Medical Parasitology, Zabol University of Medical Sciences, 61663-335 Zabol, Iran 6 PAHO/WHO Collaborating Centre for Traditional Medicine, College of Pharmacy, University of Illinois, 833 S. Wood St., Chicago, IL 60612, USA; [email protected] 7 Department of Chemistry, Biochemistry and Environmental Protection, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovica 3, 21000 Novi Sad, Serbia; [email protected] 8 Department of Agricultural and Environmental Sciences, Milan State University, 20133 Milan, Italy 9 Phytochemistry Research Center, Shahid Beheshti University of -
The Importance of Sceletium Tortuosum (L.) N.E. Brown and Its
Chapter The Importance of Sceletium tortuosum (L.) N.E. Brown and Its Viability as a Traditional African Medicinal Plant Richard James Faber, Charles Petrus Laubscher and Muhali Olaide Jimoh Abstract Sceletium tortuosum is a succulent plant that belongs to the family Mesembryanthemaceae (Aizoaceae). It is indigenous to South Africa, where it is well known by the indigenous people, especially in Namaqualand where the plant is utilized regularly for its medicinal and psycho-active properties. The main alkaloids responsible for these properties are mesembrine, mesembrenine (mesembrenone), and mesembrenol. The potential of the plant to be an alternative supplement in the promotion of health and treating a variety of psychological and psychiatric disor- ders such as depression and anxiety has stimulated interest in its pharmacological property and possibility of its commercialization. The economic value of indig- enous medicinal plants in South Africa is approximately US$60 000 000 or R4 000 000 000 annually. Thus, interest in the knowledge and use of Traditional African Medicinal Plants (TAMP) as well as meeting pharmacological and economic needs of ever-increasing human population has led to the commercialization of traditional African medicines at a fast rate. It was found that S. tortuosum has clear pharmaceutical and economical importance and is one of the only known plants to contain the alkaloids mesembrenone and mesembrine which can be utilized for the promotion of health and/or treating a variety of psychological disorders such as anxiety and depression. Keywords: African medicine, Aizoaceae, alkaloids, hydroponics, mesembrine, mesembrenine, mesembrenol, mesembryanthemaceae 1. Introduction Sceletium tortuosum (L.) N.E. Br. and Sceletium expansum L.